glp 1 agonist cardioprotective The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action JPP No 5/2021 article 10
Description
This and other trials have shown improvements in patients lipid profiles with the most pronounced impact on reduction of triglycerides
Learn how this impacts injury risk, recovery, and long-term function.
This is a huge market
And eventually, it may be evidence payers, clinicians, employers, and patients all start asking for.
- Download as a PPTX, PDF or view online for free
